Literature DB >> 6776235

Dopamine oxidation and its inhibition by (-)-deprenyl in man.

V Glover, J D Elsworth, M Sandler.   

Abstract

Dopamine is predominantly oxidized by a (-)-deprenyl sensitive form of MAO in the human striatum, and (-)-deprenyl, acting at some suitably low selective inhibitory concentration may, therefore, be of benefit in Parkinson's disease. 10(-6)M was the most effective (-)-deprenyl concentration in vitro for discriminating between the inhibition of MAO A and B. The correlation between the A/B ratio present in different human brain regions and the sensitivity of dopamine oxidation to 10(-6)M deprenyl was 0.84 (p<0.001). This suggests that all dopamine oxidation can be accounted for by the joint contribution of MAO A and B and that it is unnecessary to postulate a special form of the enzyme which metabolizes dopamine. In the brain, the striatum has the highest proportion of MAO B, and in several cortical regions, relatively more dopamine is oxidized by MAO A. In other human tissues also the deprenyl sensitivity of dopamine oxidation correlated with the known A/B ratio, the placenta, lung and jejeunum having the lowest sensitivity and being the richest in MAO A. Km values for dopamine for MAO A and B are similar, 130 and 140 uM respectively, so that the proportion oxidized by the two forms should not vary with substrate concentration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776235     DOI: 10.1007/978-3-7091-8582-7_18

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  13 in total

1.  Histochemical localisation of monoamine oxidase A and B in rat brain.

Authors:  J Willoughby; V Glover; M Sandler
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

2.  Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.

Authors:  A Prasad; V Glover; B L Goodwin; M Sandler; M Signy; S E Smith
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.

Authors:  A M O'Carroll; C J Fowler; J P Phillips; I Tobbia; K F Tipton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-04       Impact factor: 3.000

4.  Selective inhibition of MAO-A but not MAO-B activity increases rat pineal melatonin.

Authors:  G F Oxenkrug; R McCauley; I M McIntyre; C Filipowicz
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 5.  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.

Authors:  N W Milgram; G O Ivy; E Head; M P Murphy; P H Wu; W W Ruehl; P H Yu; D A Durden; B A Davis; I A Paterson
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

Review 6.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

7.  Effects of L-deprenyl on human growth hormone secretion.

Authors:  M Koulu; R Lammintausta
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

8.  Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

Authors:  N Mendis; C M Pare; M Sandler; V Glover; G M Stern
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

Authors:  B Hazelhoff; J B De Vries; D Dijkstra; W de Jong; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

10.  The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.

Authors:  J D Elsworth; M Sandler; A J Lees; C Ward; G M Stern
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.